Piet A.M Vervaet, M.D. joined ARIAD as Vice President, Drug Safety and Pharmacovigilance, in May 2014.
Prior to joining ARIAD, from April 2012 until December 2013, Dr. Vervaet served as vice president of drug safety and pharmacovigilance at Onyx Pharmaceuticals. There, he was responsible for the strategic leadership and oversight for the pharmacovigilance and drug safety function, focused on proactive and timely risk-benefit assessments of safety data, to characterize the safety profiles of the company’s oncology portfolio.
He previously held therapeutic area safety leader positions at AstraZeneca from 2003 to 2012, where he oversaw the safety of the products in various therapeutic areas, including infectious diseases, gastro-enterology, pulmonology and oncology. Before joining AstraZeneca Dr. Vervaet held various drug safety positions in the U.S. and in Europe at Johnson and Johnson, where he started his career in the pharmaceutical industry in 1988. Prior to joining industry Dr. Vervaet executed residency programs at the St-Elisabeth Hospital in Sijsele/Damme (Belgium).
Dr. Vervaet earned his Bachelor of Science and his M.D. degrees from the University of Ghent in Belgium.